Journal
VIRUSES-BASEL
Volume 13, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/v13081594
Keywords
convalescent plasma; antithrombin III; extracellular vesicles; ADAMTS13; MDA5; interferons; autoantibodies; controlled trials; decoy receptors; thrombosis; heterologous immunity
Categories
Funding
- American Heart Association (AHA) [20TPA35490415]
- National Institutes of Health (NIH) Na-tional Institute of Allergy and Infectious Disease (NIAID) [R21 AI152318, R21 AI154927, R21 AI145356]
Ask authors/readers for more resources
In addition to specific antibodies, CCP may contain other factors that could have beneficial or detrimental effects on the treatment outcomes of COVID-19 patients, which warrants further investigation.
COVID-19 convalescent plasma (CCP) is currently under investigation for both treatment and post-exposure prophylaxis. The active component of CCP mediating improved outcome is commonly reported as specific antibodies, particularly neutralizing antibodies, with clinical efficacy characterized according to the level or antibody affinity. In this review, we highlight the potential role of additional factors in CCP that can be either beneficial (e.g., AT-III, alpha-1 AT, ACE2+ extracellular vesicles) or detrimental (e.g., anti-ADAMTS13, anti-MDA5 or anti-interferon autoantibodies, pro-coagulant extracellular vesicles). Variations in these factors in CCP may contribute to varied outcomes in patients with COVID-19 and undergoing CCP therapy. We advise careful, retrospective investigation of such co-factors in randomized clinical trials that use fresh frozen plasma in control arms. Nevertheless, it might be difficult to establish a causal link between these components and outcome, given that CCP is generally safe and neutralizing antibody effects may predominate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available